| Prev Close: | 7.84 |
|---|---|
| Open: | 7.87 |
| Bid: | 7.81 x 500 |
| Ask: | 7.82 x 1300 |
| 1y Target Est: | 17.40 |
| Beta: | 2.24 |
| Next Earnings Date: | 22-Jul-13 |
| Day's Range: | 7.72 - 8.10 |
|---|---|
| 52wk Range: | 4.04 - 11.24 |
| Volume: | 560,730 |
| Avg Vol (3m): | 837,873 |
| Market Cap: | 415.46M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.41 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Sangamo BioSci announces presentation of new data demonstrating the successful application of co's proprietary In Vivo Protein Replacement Platform to produce therapeutically relevant levels of Factor VIII in a mouse modelBriefing.com(Mon, May 20)
- Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic DiseasesPR Newswire(Mon, May 20)
- SANGAMO BIOSCIENCES INC FinancialsEDGAR Online Financials(Fri, May 17)
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharmaat TheStreet(Fri, May 17)
- Sangamo BioSciences, Inc's Management Presents Bank of America Merrill Lynch Health Care ConferenceCall Transcriptat Seeking Alpha(Thu, May 16)
- Sangamo BioSciences to present new data on HIV/AIDS candidateat theflyonthewall.com(Wed, May 15)
- Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-TPR Newswire(Wed, May 15)
- 6 Superstars For Your Biotech Portfolio: John McCamantat Seeking Alpha(Fri, May 10)
- Sangamo BioSciences' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care ConferencePR Newswire(Thu, May 9)
- Why Sangamo Biosciences Shares Poppedat Motley Fool(Thu, May 9)
- SANGAMO BIOSCIENCES INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Sangamo BioSciences Reports First Quarter 2013 Financial ResultsPR Newswire(Wed, May 8)
- SANGAMO BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EEDGAR Online(Wed, May 8)
- Q1 2013 Sangamo BioSciences Earnings Release - After Market CloseCCBN(Wed, May 8)
Press Releases
- Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic DiseasesPR Newswire(Mon, May 20)
- Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic®, SB-728-TPR Newswire(Wed, May 15)
- Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care ConferencePR Newswire(Thu, May 9)
Reports
- SGMO: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 22)
- SGMO - Sangamo BioSciences Inc - Rated a Hold - Company Analysis and ASR Ranking...Alpha Street Research(May 21)
- SANGAMO BIOSCIENCES INC (SGMO) - REPORT FOR ACTIVE TRADERSPechala's Reports(May 20)